We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

Genpathway Signs Worldwide Agreement With Affymetrix

Read time: Less than a minute

Genpathway has announced that it has entered into a worldwide services agreement with Affymetrix, Inc. whereby Genpathway will provide ChIP-on-Chip assays, services, and analysis to pharmaceutical, biotechnology, and academic/institutional researchers using the Affymetrix GeneChip® Tiling Array Systems.

Affymetrix' recently launched GeneChip Tiling Array product line enables researchers to identify specific DNA sequences, including those involved in DNA-protein interactions, at the whole-genome scale.

When applied to ChIP-on- Chip, these assays enable comprehensive discovery of binding sites for transcription factors and co-regulators and the genes they regulate, as well as genes undergoing active transcription, across entire genomes.

Combining Genpathway's assays and expertise in chromatin immunoprecipitation with the Affymetrix GeneChip Tiling Arrays provides pharmaceutical, biotechnology, and academic/institutional researchers working on a wide range of genomes a complete ChIP-on-Chip discovery solution.

"With this agreement, researchers in any laboratory can have instant access to ChIP-on-Chip data generated by Affymetrix GeneChip Tiling Arrays," said Lianne McLean, senior director, Gene Expression Marketing, Affymetrix.

"This information will enable them to look beyond the known protein-coding gene sequences to thoroughly study gene structure, function, and regulation."

"We are confident with Genpathway's ability to offer the level of performance and reproducibility our users require."

"Interest in and demand for ChIP-on-Chip assays is expanding rapidly," said Benjamin Monderer, PhD, CEO of Genpathway.

"We are delighted to complete this agreement with Affymetrix and look forward to providing an immediate total solution to the current challenges presented by complicated chromatin immunoprecipitation methods when applied to tiling arrays."

Genpathway offers the following ChIP assay services using the Affymetrix tiling arrays:

- TranscriptionPath ChIP-on-Chip/Tiling™

- FactorPath ChIP-on-Chip/Tiling™

- FactorPath ChIP-on-Chip/Promoter™